Skip Navigation


European Heart Journal Advance Access originally published online on March 14, 2005
European Heart Journal 2005 26(13):1303-1308; doi:10.1093/eurheartj/ehi166
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
26/13/1303    most recent
ehi166v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (29)
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Swedberg, K.
Right arrow Articles by Poole-Wilson, P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Swedberg, K.
Right arrow Articles by Poole-Wilson, P.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The European Society of Cardiology 2005. All rights reserved. For Permissions, please e-mail: journals.permissions@oupjournals.org

Prognostic relevance of atrial fibrillation in patients with chronic heart failure on long-term treatment with beta-blockers: results from COMET

Karl Swedberg1,*, Lars G. Olsson1, Andrew Charlesworth2, John Cleland3, Peter Hanrath4, Michel Komajda5, Marco Metra6, Christian Torp-Pedersen7 and Philip Poole-Wilson8

1Department of Medicine, Sahlgrenska University Hospital/Östra, SE–416 85 Göteborg, Sweden
2Nottingham Clinical Research Group (NCRG), Nottingham, UK
3Department of Cardiology, University of Hull, Kingston upon Hull, UK
4Medical Clinic I, University Hospital, Aachen, Germany
5Department of Cardiology, La Pitié-salpétrière Hospital, Paris, France
6Cattedra di Cardiologia, Università di Brescia, Brescia, Italy
7Department of Cardiology, Bispebjerg University Hospital, Copenhagen, Denmark
8Imperial College London, UK

Received 2 September 2004; revised 18 November 2004; accepted 13 January 2005; online publish-ahead-of-print 14 March 2005.

* Corresponding author. Tel: + 46 31 343 4078; fax: + 46 31 258 933. E-mail address: karl.swedberg{at}hjl.gu.se

Aims Atrial fibrillation is common in patients with chronic heart failure (CHF). We analysed the risk associated with atrial fibrillation in a large cohort of patients with chronic heart failure all treated with a beta-blocker.

Methods and results In COMET, 3029 patients with CHF were randomized to carvedilol or metoprolol tartrate and followed for a mean of 58 months. We analysed the prognostic relevance on other outcomes of atrial fibrillation on the baseline electrocardiogram compared with no atrial fibrillation and the impact of new onset atrial fibrillation during follow-up. A multivariate analysis was performed using a Cox regression model where 10 baseline covariates were entered together with study treatment allocation. Six hundred patients (19.8%) had atrial fibrillation at baseline. These patients were older (65 vs. 61 years), included more men (88 vs.78%), had more severe symptoms [higher New York Heart Association (NYHA) class] and a longer duration of heart failure (all P<0.0001). Atrial fibrillation was associated with significantly increased mortality [relative risk (RR) 1.29: 95% CI 1.12–1.48; P<0.0001], higher all-cause death or hospitalization (RR 1.25: CI 1.13–1.38), and cardiovascular death or hospitalization for worsening heart failure (RR 1.34: CI 1.20–1.52), both P<0.0001. By multivariable analysis, atrial fibrillation no longer independently predicted mortality. Beneficial effects on mortality by carvedilol remained significant (RR 0.836: CI 0.74–0.94; P=0.0042). New onset atrial fibrillation during follow-up (n=580) was associated with significant increased risk for subsequent death in a time-dependent analysis (RR 1.90: CI 1.54–2.35; P<0.0001) regardless of treatment allocation and changes in NYHA class.

Conclusion In CHF, atrial fibrillation significantly increases the risk for death and heart failure hospitalization, but is not an independent risk factor for mortality after adjusting for other predictors of prognosis. Treatment with carvedilol compared with metoprolol offers additional benefits among patients with atrial fibrillation. Onset of new atrial fibrillation in patients on long-term beta-blocker therapy is associated with significant increased subsequent risk of mortality and morbidity.

Key Words: Chronic heart failure • Atrial fibrillation • Beta-blockers • Prognosis


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 NEJMHome page
J. E. Poole, G. W. Johnson, A. S. Hellkamp, J. Anderson, D. J. Callans, M. H. Raitt, R. K. Reddy, F. E. Marchlinski, R. Yee, T. Guarnieri, et al.
Prognostic Importance of Defibrillator Shocks in Patients with Heart Failure
N. Engl. J. Med., September 4, 2008; 359(10): 1009 - 1017.
[Abstract] [Full Text] [PDF]

Home page
 Eur Heart JHome page
M. Rivero-Ayerza, W. Scholte op Reimer, M. Lenzen, D. A.M.J. Theuns, L. Jordaens, M. Komajda, F. Follath, K. Swedberg, and J. G.F. Cleland
New-onset atrial fibrillation is an independent predictor of in-hospital mortality in hospitalized heart failure patients: results of the EuroHeart Failure Survey
Eur. Heart J., July 1, 2008; 29(13): 1618 - 1624.
[Abstract] [Full Text] [PDF]

Home page
 EuropaceHome page
S. Buck, M. Rienstra, A. H. Maass, W. Nieuwland, D. J. Van Veldhuisen, and I. C. Van Gelder
Cardiac resynchronization therapy in patients with heart failure and atrial fibrillation: importance of new-onset atrial fibrillation and total atrial conduction time
Europace, May 1, 2008; 10(5): 558 - 565.
[Abstract] [Full Text] [PDF]

Home page
 Eur Heart JHome page
H.-R. Neuberger, C. Mewis, D. J. van Veldhuisen, U. Schotten, I. C. van Gelder, M. A. Allessie, and M. Bohm
Management of atrial fibrillation in patients with heart failure
Eur. Heart J., November 1, 2007; 28(21): 2568 - 2577.
[Abstract] [Full Text] [PDF]

Home page
 J Am Coll CardiolHome page
L. Olsson, M. A. Pfeffer, and K. Swedberg
Reply
J. Am. Coll. Cardiol., January 23, 2007; 49(3): 376 - 377.
[Full Text] [PDF]

Home page
 HeartHome page
A J Camm, I Savelieva, G Y H Lip, and on behalf of the Guideline Development Group for t
Rate control in the medical management of atrial fibrillation
Heart, January 1, 2007; 93(1): 35 - 38.
[Full Text] [PDF]

Home page
 Eur Heart JHome page
O. D. Pedersen, P. Sondergaard, T. Nielsen, S. J. Nielsen, E. S. Nielsen, N. Falstie-Jensen, I. Nielsen, L. Kober, H. Burchardt, M. Seibaek, et al.
Atrial fibrillation, ischaemic heart disease, and the risk of death in patients with heart failure
Eur. Heart J., December 1, 2006; 27(23): 2866 - 2870.
[Abstract] [Full Text] [PDF]

Home page
 CirculationHome page
U. C. Hoppe, J. M. Casares, H. Eiskjaer, A. Hagemann, J. G.F. Cleland, N. Freemantle, and E. Erdmann
Effect of Cardiac Resynchronization on the Incidence of Atrial Fibrillation in Patients With Severe Heart Failure
Circulation, July 4, 2006; 114(1): 18 - 25.
[Abstract] [Full Text] [PDF]

Home page
 J Am Coll CardiolHome page
L. G. Olsson, K. Swedberg, A. Ducharme, C. B. Granger, E. L. Michelson, J. J.V. McMurray, M. Puu, S. Yusuf, M. A. Pfeffer, and on behalf of the CHARM Investigators
Atrial Fibrillation and Risk of Clinical Events in Chronic Heart Failure With and Without Left Ventricular Systolic Dysfunction: Results From the Candesartan in Heart failure-Assessment of Reduction in Mortality and morbidity (CHARM) Program
J. Am. Coll. Cardiol., May 16, 2006; 47(10): 1997 - 2004.
[Abstract] [Full Text] [PDF]

Home page
 Eur Heart JHome page
D. J. van Veldhuisen, H. J.G.M. Crijns, and M. P. van den Berg
Heart failure, atrial fibrillation, and beta-blockers
Eur. Heart J., January 2, 2006; 27(2): 247 - 247.
[Full Text] [PDF]


Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.